Aquestive Drug Patent Portfolio
Aquestive owns 3 orange book drugs protected by 5 US patents Given below is the list of Aquestive's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11273131 | Pharmaceutical compositions with enhanced permeation | 18 Jun, 2038 | Active |
| US9095577 | Stabilized amine-containing actives in oral film compositions | 13 Jul, 2030 | Active |
| US8580830 | Non-mucoadhesive film dosage forms | 23 Nov, 2029 | Active |
| US8603514 | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions | 03 Apr, 2024 | Expired |
| US8765167 | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions | 20 Feb, 2024 | Expired |
Latest Legal Activities on Aquestive's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Aquestive.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 03 Sep, 2025 | US11273131 |
| Maintenance Fee Reminder Mailed | 28 Jul, 2025 | US8603514 (Litigated) |
| Maintenance Fee Reminder Mailed | 30 Jun, 2025 | US8580830 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 30 Jan, 2023 | US9095577 |
| Patent Issue Date Used in PTA Calculation | 15 Mar, 2022 | US11273131 |
| Recordation of Patent Grant Mailed | 15 Mar, 2022 | US11273131 |
| Email Notification | 24 Feb, 2022 | US11273131 |
| Issue Notification Mailed | 23 Feb, 2022 | US11273131 |
| Application Is Considered Ready for Issue | 15 Feb, 2022 | US11273131 |
| Dispatch to FDC | 15 Feb, 2022 | US11273131 |
| Mailing Corrected Notice of Allowability | 14 Feb, 2022 | US11273131 |
| Email Notification | 14 Feb, 2022 | US11273131 |
| Corrected Notice of Allowability | 27 Jan, 2022 | US11273131 |
| Pubs Case Remand to TC | 25 Jan, 2022 | US11273131 |
| Printer Rush- No mailing | 13 Jan, 2022 | US11273131 |
Aquestive's Drug Patent Litigations
Aquestive's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 28, 2014, against patent number US8765167. The petitioner BioDelivery Sciences International, Inc., challenged the validity of this patent, with MonoSol Rx, LLC. et al. as the respondent. Click below to track the latest information on how companies are challenging Aquestive's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8603514 | June, 2017 |
Institution Denied
(20 Oct, 2017)
| MonoSol Rx, LLC et al. | Par Pharmaceutical, Inc. et al. |
| US8603514 | June, 2017 |
Institution Denied
(20 Oct, 2017)
| MonoSol Rx, LLC et al. | Dr. Reddy’s Laboratories, Inc. et al. |
| US8603514 | November, 2016 |
Terminated-Settled
(06 Oct, 2017)
| MonoSol Rx, LLC et al. | Mylan Technologies, Inc. et al. |
| US8603514 | May, 2016 |
Institution Denied
(05 Dec, 2016)
| MonoSol Rx, LLC et al. | Dr. Reddy's Laboratories, Inc. et al. |
| US8603514 | December, 2015 |
Institution Denied
(23 May, 2016)
| MONOSOL RX LLC et al. | Teva Pharmaceuticals USA Inc |
| US8765167 | October, 2014 |
Final Written Decision
(24 Mar, 2016)
| MonoSol Rx, LLC. et al. | BioDelivery Sciences International, Inc. |
| US8765167 | October, 2014 |
Terminated-Settled
(24 Mar, 2016)
| MonoSol Rx, LLC. et al. | BioDelivery Sciences International, Inc. |
| US8765167 | October, 2014 |
Institution Denied
(20 May, 2015)
| MonoSol Rx, LLC. et al. | BioDelivery Sciences International, Inc. |
Aquestive Drug Patents' Oppositions Filed in EPO
Aquestive drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 11, 2012, by Lts Lohmann Therapie-Systeme Ag. This opposition was filed on patent number EP02801042A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP11157819A | Jun, 2014 | Ahrens, Gabriele | Patent maintained as amended |
| EP02782151A | Jun, 2013 | Acino Pharma AG | Revoked |
| EP02782151A | Jun, 2013 | Germann, Sandra | Revoked |
| EP02801042A | Sep, 2012 | Ahrens, Gabriele | Patent maintained as amended |
| EP02801042A | Sep, 2012 | LTS LOHMANN Therapie-Systeme AG | Patent maintained as amended |
Aquestive's Family Patents
Recent FDA approvals and tentative approvals for Aquestive
This section lists recent FDA approvals and tentative approvals for Lupin, covering innovator and generic drugs with key regulatory details and timelines.
Innovator drugs
Includes innovator drug submissions that appear in FDA approval and tentative approval disclosures.
| Drug Name | Submission class (FDA) | Submission Category | Submission Date |
|---|---|---|---|
| Libervant |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval | 30 Aug, 2022 |
Aquestive Drug List
Given below is the complete list of Aquestive's drugs and the patents protecting them.
1. Exservan
Exservan is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8603514 | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
03 Apr, 2024
(1 year, 11 months ago)
| Expired |
| US8765167 | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
20 Feb, 2024
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Exservan's drug page
2. Libervant
Libervant is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11273131 | Pharmaceutical compositions with enhanced permeation |
18 Jun, 2038
(12 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Libervant's drug page
3. Zuplenz
Zuplenz is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9095577 | Stabilized amine-containing actives in oral film compositions |
13 Jul, 2030
(4 years from now)
| Active |
| US8580830 | Non-mucoadhesive film dosage forms |
23 Nov, 2029
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zuplenz's drug page